Association Study of Val66Met Polymorphism in Brain-Derived Neurotrophic Factor Gene with Clozapine-Induced Metabolic Syndrome: Preliminary Results

PLoS ONE

Volumn 8, Issue 8, 2013, Pages

  Zhang, Yi ^a   Chen, Meijuan ^a   Wu, Zhiguo ^a   Chen, Jun ^a   Yu, Shunying ^a   Fang, Yiru ^a   Zhang, Chen ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; CLOZAPINE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; ARTICLE; BRAIN DERIVED NEUROTROPHIC FACTOR GENE; CHOLESTEROL BLOOD LEVEL; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; DRUG SAFETY; FEMALE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GLUCOSE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MOLECULAR PATHOLOGY; PHARMACOGENETICS; SCHIZOPHRENIA; SEX DIFFERENCE; TRIACYLGLYCEROL BLOOD LEVEL;

ALLELES; AMINO ACID SUBSTITUTION; BRAIN-DERIVED NEUROTROPHIC FACTOR; CLOZAPINE; CODON; CROSS-SECTIONAL STUDIES; FEMALE; GENETIC ASSOCIATION STUDIES; GENOTYPE; HUMANS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; SEROTONIN ANTAGONISTS;

EID: 84881537785     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0072652     Document Type: Article

References (48)

1. Pramyothin P, Khaodhiar L, (2010) Metabolic syndrome with the atypical antipsychotics. Curr Opin Endocrinol Diabetes Obes 17: 460-466.
2. Asenjo Lobos C, Komossa K, Rummel-Kluge C, Hunger H, Schmid F, et al. (2010) Clozapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev: CD006633.
3. McEvoy JP, Lieberman JA, Stroup TS, Davis SM, Meltzer HY, et al. (2006) Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry 163: 600-610.
4. De Hert M, Schreurs V, Sweers K, Van Eyck D, Hanssens L, et al. (2008) Typical and atypical antipsychotics differentially affect long-term incidence rates of the metabolic syndrome in first-episode patients with schizophrenia: a retrospective chart review. Schizophr Res 101: 295-303.
5. Mitchell AJ, Vancampfort D, Sweers K, van Winkel R, Yu W, et al. (2013) Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders--a systematic review and meta-analysis. Schizophr Bull 39: 306-318.
6. Lee IT, Lee WJ, Tsai IC, Liang KW, Lin SY, et al. (2012) Brain-derived neurotrophic factor not associated with metabolic syndrome but inversely correlated with vascular cell adhesion molecule-1 in men without diabetes. Clin Chim Acta 413: 944-948.
7. Lyons WE, Mamounas LA, Ricaurte GA, Coppola V, Reid SW, et al. (1999) Brain-derived neurotrophic factor-deficient mice develop aggressiveness and hyperphagia in conjunction with brain serotonergic abnormalities. Proc Natl Acad Sci U S A 96: 15239-15244.
8. Gray J, Yeo GS, Cox JJ, Morton J, Adlam AL, et al. (2006) Hyperphagia, severe obesity, impaired cognitive function, and hyperactivity associated with functional loss of one copy of the brain-derived neurotrophic factor (BDNF) gene. Diabetes 55: 3366-3371.
9. Fox EA, Byerly MS, (2004) A mechanism underlying mature-onset obesity: evidence from the hyperphagic phenotype of brain-derived neurotrophic factor mutants. Am J Physiol Regul Integr Comp Physiol 286: R994-1004.
10. Duan W, Guo Z, Jiang H, Ware M, Mattson MP, (2003) Reversal of behavioral and metabolic abnormalities, and insulin resistance syndrome, by dietary restriction in mice deficient in brain-derived neurotrophic factor. Endocrinology 144: 2446-2453.
11. Ribases M, Gratacos M, Fernandez-Aranda F, Bellodi L, Boni C, et al. (2005) Association of BDNF with restricting anorexia nervosa and minimum body mass index: a family-based association study of eight European populations. Eur J Hum Genet 13: 428-434.
12. Zhang XY, Zhou DF, Wu GY, Cao LY, Tan YL, et al. (2008) BDNF levels and genotype are associated with antipsychotic-induced weight gain in patients with chronic schizophrenia. Neuropsychopharmacology 33: 2200-2205.
13. Zai GC, Zai CC, Chowdhury NI, Tiwari AK, Souza RP, et al. (2012) The role of brain-derived neurotrophic factor (BDNF) gene variants in antipsychotic response and antipsychotic-induced weight gain. Prog Neuropsychopharmacol Biol Psychiatry 39: 96-101.
14. Tsai A, Liou YJ, Hong CJ, Wu CL, Tsai SJ, et al. (2011) Association study of brain-derived neurotrophic factor gene polymorphisms and body weight change in schizophrenic patients under long-term atypical antipsychotic treatment. Neuromolecular Med 13: 328-333.
15. Zhang XY, Tan YL, Zhou DF, Cao LY, Wu GY, et al. (2007) Serum BDNF levels and weight gain in schizophrenic patients on long-term treatment with antipsychotics. J Psychiatr Res 41: 997-1004.
16. Zhang JP, Lencz T, Geisler S, DeRosse P, Bromet EJ, et al. (2013) Genetic variation in BDNF is associated with antipsychotic treatment resistance in patients with schizophrenia. Schizophrenia Research 146: 285-288.
17. Egan MF, Kojima M, Callicott JH, Goldberg TE, Kolachana BS, et al. (2003) The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell 112: 257-269.
18. Ma XY, Qiu WQ, Smith CE, Parnell LD, Jiang ZY, et al. (2012) Association between BDNF rs6265 and obesity in the Boston Puerto Rican Health Study. J Obes 2012: 102942.
19. Wu L, Xi B, Zhang M, Shen Y, Zhao X, et al. (2010) Associations of six single nucleotide polymorphisms in obesity-related genes with BMI and risk of obesity in Chinese children. Diabetes 59: 3085-3089.
20. Friedel S, Horro FF, Wermter AK, Geller F, Dempfle A, et al. (2005) Mutation screen of the brain derived neurotrophic factor gene (BDNF): identification of several genetic variants and association studies in patients with obesity, eating disorders, and attention-deficit/hyperactivity disorder. Am J Med Genet B Neuropsychiatr Genet 132B: 96-99.
21. Burghardt KJ, Pop-Busui R, Bly MJ, Grove TB, Taylor SF, et al. (2012) The influence of the brain-derived neurotropic factor Val66Met genotype and HMG-CoA reductase inhibitors on insulin resistance in the schizophrenia and bipolar populations. Clin Transl Sci 5: 486-490.
22. Yi Z, Zhang C, Wu Z, Hong W, Li Z, et al. (2011) Lack of effect of brain derived neurotrophic factor (BDNF) Val66Met polymorphism on early onset schizophrenia in Chinese Han population. Brain Res 1417: 146-150.
23. Lu W, Zhang C, Yi Z, Li Z, Wu Z, et al. (2012) Association between BDNF Val66Met polymorphism and cognitive performance in antipsychotic-naive patients with schizophrenia. J Mol Neurosci 47: 505-510.
24. Ryu S, Oh S, Cho EY, Nam HJ, Yoo JH, et al. (2011) Interaction between genetic variants of DLGAP3 and SLC1A1 affecting the risk of atypical antipsychotics-induced obsessive-compulsive symptoms. Am J Med Genet B Neuropsychiatr Genet 156B: 949-959.
25. Cai J, Zhang W, Yi Z, Lu W, Wu Z, et al. (2013) Influence of polymorphisms in genes SLC1A1, GRIN2B, and GRIK2 on clozapine-induced obsessive-compulsive symptoms. Psychopharmacology (Berl) doi: 10.1007/s00213-013-3137-2.
26. Zhou H, Guo ZR, Yu LG, Hu XS, Xu BH, et al. (2010) Evidence on the applicability of the ATPIII, IDF and CDS metabolic syndrome diagnostic criteria to identify CVD and T2DM in the Chinese population from a 6.3-year cohort study in mid-eastern China. Diabetes Res Clin Pract 90: 319-325.
27. Bao YQ, Lu JX, Wang C, Yang M, Li HT, et al. (2008) Optimal waist circumference cutoffs for abdominal obesity in Chinese. Atherosclerosis 201: 378-384.
28. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, et al. (2005) Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 112: 2735-2752.
29. Zhang W, Chen X, Gong W, Tang J, Tan L, et al. (2010) Common promoter variants of the NDUFV2 gene do not confer susceptibility to schizophrenia in Han Chinese. Behav Brain Funct 6: 75.
30. Shi YY, He L, (2006) SHEsis, a powerful software platform for analyses of linkage disequilibrium, haplotype construction, and genetic association at polymorphism loci (vol 15, pg 97, 2005). Cell Research 16: 851-851.
31. Kuipers SD, Bramham CR, (2006) Brain-derived neurotrophic factor mechanisms and function in adult synaptic plasticity: new insights and implications for therapy. Curr Opin Drug Discov Devel 9: 580-586.
32. Travaglia A, La Mendola D, Magri A, Nicoletti VG, Pietropaolo A, et al. (2012) Copper, BDNF and Its N-terminal domain: inorganic features and biological perspectives. Chemistry 18: 15618-15631.
33. Chaldakov GN, Tonchev AB, Aloe L, (2009) NGF and BDNF: from nerves to adipose tissue, from neurokines to metabokines. Riv Psichiatr 44: 79-87.
34. Nicholson JR, Peter JC, Lecourt AC, Barde YA, Hofbauer KG, (2007) Melanocortin-4 receptor activation stimulates hypothalamic brain-derived neurotrophic factor release to regulate food intake, body temperature and cardiovascular function. J Neuroendocrinol 19: 974-982.
35. Coppola V, Tessarollo L, (2004) Control of hyperphagia prevents obesity in BDNF heterozygous mice. Neuroreport 15: 2665-2668.
36. Levin BE, (2007) Neurotrophism and energy homeostasis: perfect together. Am J Physiol Regul Integr Comp Physiol 293: R988-991.
37. Chaldakov GN, Fiore M, Stankulov IS, Hristova M, Antonelli A, et al. (2001) NGF, BDNF, leptin, and mast cells in human coronary atherosclerosis and metabolic syndrome. Arch Physiol Biochem 109: 357-360.
38. Blankenberg S, Rupprecht HJ, Bickel C, Peetz D, Hafner G, et al. (2001) Circulating cell adhesion molecules and death in patients with coronary artery disease. Circulation 104: 1336-1342.
39. Malik I, Danesh J, Whincup P, Bhatia V, Papacosta O, et al. (2001) Soluble adhesion molecules and prediction of coronary heart disease: a prospective study and meta-analysis. Lancet 358: 971-976.
40. Pelleymounter MA, Cullen MJ, Wellman CL, (1995) Characteristics of BDNF-induced weight loss. Exp Neurol 131: 229-238.
41. Levinger I, Goodman C, Matthews V, Hare DL, Jerums G, et al. (2008) BDNF, metabolic risk factors, and resistance training in middle-aged individuals. Med Sci Sports Exerc 40: 535-541.
42. Krabbe KS, Nielsen AR, Krogh-Madsen R, Plomgaard P, Rasmussen P, et al. (2007) Brain-derived neurotrophic factor (BDNF) and type 2 diabetes. Diabetologia 50: 431-438.
43. Yamanaka M, Itakura Y, Tsuchida A, Nakagawa T, Taiji M, (2008) Brain-derived neurotrophic factor (BDNF) prevents the development of diabetes in prediabetic mice. Biomed Res 29: 147-153.
44. Ono M, Itakura Y, Nonomura T, Nakagawa T, Nakayama C, et al. (2000) Intermittent administration of brain-derived neurotrophic factor ameliorates glucose metabolism in obese diabetic mice. Metabolism 49: 129-133.
45. Raz N, Dahle CL, Rodrigue KM, Kennedy KM, Land SJ, et al. (2008) Brain-derived neurotrophic factor Val66Met and blood glucose: a synergistic effect on memory. Front Hum Neurosci 2: 12.
46. Cai J, Yi Z, Lu W, Fang Y, Zhang C, (2013) Crosstalk between 5-HT2cR and PTEN signaling pathway in atypical antipsychotic-induced metabolic syndrome and cognitive dysfunction. Med Hypotheses 80: 486-489.
47. Frisardi V, Solfrizzi V, Capurso C, Imbimbo BP, Vendemiale G, et al. (2010) Is insulin resistant brain state a central feature of the metabolic-cognitive syndrome? J Alzheimers Dis 21: 57-63.
48. Hill RA, van den Buuse M, (2011) Sex-dependent and region-specific changes in TrkB signaling in BDNF heterozygous mice. Brain Res 1384: 51-60.